GLP-1 Dose Escalation Schedule

Both Semaglutide and Tirzepatide start at low doses and gradually increase over several months. This is not optional — the escalation schedule exists because starting at the full dose causes severe nausea, vomiting, and other gastrointestinal side effects in most patients.

The gradual increase allows your GLP-1 receptors, gastric emptying rate, and appetite centers to adapt to the medication. Most patients experience their worst side effects during the first 1-2 weeks at each new dose level, with symptoms improving as the body adjusts. Skipping dose levels or escalating too quickly dramatically increases side effect severity and dropout rates.

The Wegovy dose escalation takes 16 weeks to reach the maintenance dose of 2.4 mg. Each of the five dose levels (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) is maintained for exactly 4 weeks. The Ozempic schedule for type 2 diabetes is similar but with a lower maximum dose of 1.0 mg (or 2.0 mg for the newer formulation).

Weight loss accelerates with each dose increase and is most rapid during the first 6-9 months at the maintenance dose. If you experience intolerable nausea at a particular dose, your physician may extend that dose level for an additional 4 weeks before escalating rather than pushing through.

The Mounjaro/Zepbound dose escalation takes 20 weeks to reach the maximum dose of 15 mg, with six dose levels (2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg, 12.5 mg, 15.0 mg) each lasting 4 weeks. However, many patients maintain at 10 mg or 12.5 mg if weight loss is satisfactory and side effects are well-controlled at those levels.

Because Tirzepatide is a dual agonist (targeting both GLP-1 and GIP receptors), it often produces more weight loss per dose level than Semaglutide. Some patients reach their goal weight at moderate doses and do not need to escalate to the maximum.